Earnings ·
Reports Q3 net loss of $20.5M and raises cash position to $193.3M
IKTInhibikase Therapeutics, Inc.
Inhibikase Therapeutics reported a net loss of $20.5 million, or $0.10 per share, for the quarter ended September 30, 2026, compared to a net loss of $11.9 million in the prior-year period. Research and development expenses rose to $15.0 million from $7.6 million as the company advances its Phase 3 IMPROVE-PAH study for IKT-001. The firm holds $193.3 million in cash, cash equivalents, and marketable securities, supported by a $50 million equity financing completed in July with RA Capital Management. Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases.